Findings of early cerebral Amyloid-beta deposition in mice after peripheral injection of Amyloid-beta containing brain extracts, and humans following cadaveric human growth hormone treatment raised concerns that Amyloid-beta aggregates and possibly Alzheimer disease (AD) may be transmissible between individuals. Yet, proof that Amyloid-beta actually reaches the brain from the peripheral injection site is lacking. Here, we used a proteomic approach combining stable isotope labeling of mammals and untargeted and targeted mass spectrometry. Specifically, we generated 13C-isotope labeled brain extracts from mice expressing human Amyloid-beta and track 13C-Lys-labeled Amyloid-beta after intraperitoneal administration into young Amyloid betaPP transgenic mice. We detected injected Amyloid-beta in the liver and lymphoid tissues for up to 100 days. In contrast, injected 13C-Lys-labeled Amyloid-beta was not detectable in the brain whereas the mice incorporated 13C-Lys from the donor brain extracts into endogenous Amyloid-beta. Using a highly sensitive and specific proteomic approach, we demonstrated that Amyloid-beta does not reach the brain from the periphery. Our study argues against potential transmissibility of AD while opening new avenues to uncover mechanisms of pathophysiological protein deposition.
Please note that corresponding MRM data for this project have been submitted elsewhere.
[doi:10.25345/C57H1DR1J]
[dataset license: CC0 1.0 Universal (CC0 1.0)]
Keywords: Alzheimer disease, APP-transgenic mice, brain, targeted and untargeted immuno-mass spectrometry, seeding
Principal Investigators: (in alphabetical order) |
Jens Pahnke, 1) Department of Pathology, Section of Neuropathology, Translational Neurodegeneration Research and Neuropathology Lab, University of Oslo and Oslo University Hospital, 0372 Oslo, Norway 2) LIED, University of Lubeck, 23538 Lubeck, Germany 3) Department of Pharmacology, Faculty of Medicine, University of Latvia, 1004 Riga, Latvia, Norway Maciej Lalowski, Helsinki Institute for Life Science (HiLIFE) and Faculty of Medicine, Biochemistry/Developmental Biology, Meilahti Clinical Proteomics Core Facility, University of Helsinki, Helsinki, FI-00014, Finland Mirjam Brackhan, 1) Department of Pathology, Section of Neuropathology, Translational Neurodegeneration Research and Neuropathology Lab, University of Oslo and Oslo University Hospital, 0372 Oslo, Norway 2) LIED, University of Lubeck, 23538 Lubeck, Germany, Norway |
Submitting User: | MaciejLalowski_2 |
M. Brackhan, G. Calza, K.Lundgren, P. Bascuñana. T. Brüning, R. Soliymani, R. Kumar, A. Abelein, M. Baumann, M. Lalowski. J. Pahnke.
Isotope-labeled amyloid-? does not transmit to the brain in a prion-like manner after peripheral administration.
EMBO Reports (2022)e54405. doi.org/10.15252/embr.202154405.
Number of Files: | |
Total Size: | |
Spectra: | |
Subscribers: | |
Owner | Reanalyses | |
---|---|---|
Experimental Design | ||
Conditions:
|
||
Biological Replicates:
|
||
Technical Replicates:
|
||
Identification Results | ||
Proteins (Human, Remapped):
|
||
Proteins (Reported):
|
||
Peptides:
|
||
Variant Peptides:
|
||
PSMs:
|
||
Quantification Results | ||
Differential Proteins:
|
||
Quantified Proteins:
|
||
Browse Dataset Files | |
FTP Download Link (click to copy):
|